Caprock Group LLC Acquires 148 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Caprock Group LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,062 shares of the medical research company’s stock after buying an additional 148 shares during the quarter. Caprock Group LLC’s holdings in Thermo Fisher Scientific were worth $5,239,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Legacy Investment Solutions LLC bought a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $26,000. Peterson Financial Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at $27,000. Missouri Trust & Investment Co acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. Endeavor Private Wealth Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth $30,000. Finally, Decker Retirement Planning Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at $43,000. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total value of $5,581,200.00. Following the transaction, the chief executive officer now owns 33,608 shares in the company, valued at approximately $18,757,296.96. This represents a 22.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 29,000 shares of company stock worth $15,859,540 over the last three months. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a research note on Friday, January 10th. Citigroup increased their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a report on Friday. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Royal Bank of Canada reduced their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $655.64.

Thermo Fisher Scientific Stock Down 1.4 %

Thermo Fisher Scientific stock opened at $598.40 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The stock has a market cap of $228.89 billion, a PE ratio of 37.52, a price-to-earnings-growth ratio of 3.89 and a beta of 0.76. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The firm’s 50-day simple moving average is $539.66 and its 200 day simple moving average is $570.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were issued a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.